Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients

Anti-Cancer Drugs

Volumn 24, Issue 2, 2013, Pages 212-218

  Berretta, Massimiliano ^a   Di Benedetto, Fabrizio ^c   Dal Maso, Luigino ^b   Cacopardo, Bruno ^e   Nasti, Guglielmo ^f   Facchini, Gaetano ^f   Bearz, Alessandra ^a   Spina, Michele ^a   Garlassi, Elisa ^d   De Re, Valli ^a   Fiorica, Francesco ^g   Lleshi, Arben ^a   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Epidemiology and Biostatistics Unit   (Italy)

^c Liver and Multivisceral Transplant Center   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g S ANNA HOSPITAL   (Italy)

Author keywords

AIDS; HAART; hepatocellular carcinoma; HIV; sorafenib

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SORAFENIB;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPOPHOSPHATEMIA; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; UNRESECTABLE HEPATOCELLULAR CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84873084116     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835c032f     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156
2. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1998 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003; 21:4329-4335
3. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez Tapias JM, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2: 1004-1006
4. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, et al. Characteristics difference of hepatocellular carcinoma between hepatitis B- And C- viral infection in Japan. Hepatology 1995; 22:1027-1033
5. Bonacini M, Govindarajan S, Blatt LM, Schmid P, Conrad A, Lindsay KL. patients co-Infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999; 6:203-208
6. Soto B, Sa'nchez-Quijano A, Rodrigo L, del Olmo JA, Garci'a-Bengoechea M, Herna'ndez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-Acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1-5
7. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183:1112-1115
8. Serraino D, Zucchetto A, Suligoi B, Bruzzone S, Camoni L, Boros S, et al. Survival after AIDS diagnosis in Italy, 1999-2006: A populationbased study. J Acquir Immune Defic Syndr 2009; 52:99-105
9. Berretta M, Cinelli R, Martellotta F, Spina M, Vaccher E, Tirelli U. Therapeutic approaches to AIDS-related malignancies. Oncogene 2003; 22:6646-6659
10. Sulkowski M. Hepatocellular carcinoma in HIV-Infected patients comes of age: The convergence of epidemiology and treatment effectiveness. J Hepatol 2009; 50:655-658
11. Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, et al. for the Cancer and AIDS Registries Linkage (CARL) Study. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 2009; 100: 840-847
12. Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. North American Liver Cancer in HIV Study Group. Presentation and outcome of hepatocellular carcinoma in HIV-Infected patients: A US-Canadian multicenter study. J Hepatol 2007; 47:527-537
13. Murillas J, Del Rio M, Riera M, Vaquer P, Salas A, Leyes M, et al. Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. Eur J Intern Med 2005; 16:113-115
14. Sulkowski M, Thomas DL. Hepatitis C in the HIV-Infected patient. Clin Liver Dis 2003; 7:179-194
15. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking antiretroviral therapy: An observational cohort study. Lancet 2007; 370:407-413
16. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40:225-235
17. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma. The BCLC staging classification. Semin Liver Dis 1999; 19:329-338
18. Llovet JM, Fuster J, Bruix J. Barcelona-Clinic Liver Cancer Group: The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10 (SUPPL1):S115-S120
19. Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: Two ends of the therapeutic spectrum. Lancet Oncol 2004; 5:409-418
20. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral anti-Tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109
21. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390
22. Chelis L, Ntinos N, Souftas V, Deftereos S, Xenidis N, Chamalidou E, et al. Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co-Infected patient: Possible synergy with HAART? A case report. Med Oncol 2011; 28 (SUPPL1):S165-S168
23. Perboni G, Costa P, Fibbia GC, Morandini B, Scalzini A, Tagliani A, et al. Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient A case report. Oncologist 2010; 15:142-145
24. Ozenne V, Gervais A, Peytavin G, Castelnau C, Valla DC, Degos F. Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: A case report. Hepatogastroenterology 2011; 58: 161-162
25. De Nardo P, Viscione M, Corpolongo A, Bellagamba R, Vennarecci G, Ettorre GM, et al. Treatment of recurrent hepatocellular carcinoma with sorafenib in a HIV/HCV co-Infected patient in HAART: A case report. Infect Agent cancer 2012; 7:15
26. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006; 57:685-692
27. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430
28. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
29. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
30. Armitage P, Berry G. Statistical methods in medical research. II ed. Oxford, UK: Blackwell Scientific Publications; 1987
31. Eisenhauer EA, Therasse P, Borgaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
32. Berretta M, Zanet E, Di Benedetto F, Simonelli C, Bearz A, Morra A, et al. Unusual presentation of metastatic hepatocellular carcinoma in an HIV/HCV coinfected patient: Case report and review of the literature. Tumori 2008; 94:589-591
33. Tavio M, Grossi P, Baccarani U, Scudeller L, Pea F, Berretta M, et al. HIV-Infected patients and liver transplantation: Who, when and why. Curr HIV Res 2011; 9:120-127
34. Berretta M, Garlassi E, Cacopardo B, Cappellani A, Guaraldi G, Cocchi S, et al. Hepatocellular carcinoma in HIV-Infected patients: Check early, treat hard. Oncologist 2011; 16:1258-1269
35. Di Benedetto F, Di Sandro S, De Ruvo N, Berretta M, Montalti R, Guerrini GP, et al. Human immunodeficiency virus and liver transplantation: Our point of view. Transplant Proc 2008; 40:1965-1971
36. Di Benedetto F, De Ruvo N, Berretta M, Masetti M, Montalti R, Di Sandro S, et al. Hepatocellular carcinoma in HIV patients treated by liver transplantation. Eur J Surg Oncol 2008; 34:422-427
37. Di Benedetto F, De Ruvo N, Berretta M, Masetti M, Montalti R, Di Sandro S, et al. Don't deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era. J Clin Oncol 2006; 24:e26-e27
38. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14:70-76
39. Cheng A, Kang Y, Chen Z, Tsao Qin S, Kim J, Burock K, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 2008; 26 (SUPPL20):4509a.
40. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24:4293-4300
41. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134
42. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDSdefining cancers in patients with HIV on HAART therapy: Treatment considerations and research outlook. Curr Opin Oncol 2009; 21: 445-454
43. Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP. Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practise. Crit Rev Oncol Hematol 2009; 72:10-20